These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 1661297

  • 1. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.
    Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA.
    J Clin Invest; 1991 Dec; 88(6):2095-105. PubMed ID: 1661297
    [Abstract] [Full Text] [Related]

  • 2. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T, van der Eerden BC, Hoenderop JG, Weinans H, van Leeuwen JP, Bindels RJ.
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [Abstract] [Full Text] [Related]

  • 3. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P, Nguyen H, Barbier A, Baron R.
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [Abstract] [Full Text] [Related]

  • 4. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism.
    Owens JM, Fuller K, Chambers TJ.
    J Cell Physiol; 1997 Jul; 172(1):79-86. PubMed ID: 9207928
    [Abstract] [Full Text] [Related]

  • 5. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
    Sato M, Grasser W.
    J Bone Miner Res; 1990 Jan; 5(1):31-40. PubMed ID: 2106763
    [Abstract] [Full Text] [Related]

  • 6. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M.
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [Abstract] [Full Text] [Related]

  • 7. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.
    Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP.
    J Bone Miner Res; 1994 Nov; 9(11):1777-87. PubMed ID: 7863829
    [Abstract] [Full Text] [Related]

  • 8. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin.
    Zimolo Z, Wesolowski G, Rodan GA.
    J Clin Invest; 1995 Nov; 96(5):2277-83. PubMed ID: 7593614
    [Abstract] [Full Text] [Related]

  • 9. Reversible inhibition of osteoclastic activity by bone-bound gallium (III).
    Blair HC, Teitelbaum SL, Tan HL, Schlesinger PH.
    J Cell Biochem; 1992 Apr; 48(4):401-10. PubMed ID: 1577877
    [Abstract] [Full Text] [Related]

  • 10. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.
    Clin Cancer Res; 2005 Jun 01; 11(11):4198-203. PubMed ID: 15930357
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of alendronate on bone resorption of autogenous free bone grafts in rats.
    Altundal H, Sayrak H, Yurtsever E, Göker K.
    J Oral Maxillofac Surg; 2007 Mar 01; 65(3):508-16. PubMed ID: 17307600
    [Abstract] [Full Text] [Related]

  • 12. [Osteoclasts in bone metabolism].
    Hakeda Y, Kumegawa M.
    Kaibogaku Zasshi; 1991 Aug 01; 66(4):215-25. PubMed ID: 1759556
    [Abstract] [Full Text] [Related]

  • 13. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA.
    Bone; 2006 May 01; 38(5):628-36. PubMed ID: 16185944
    [Abstract] [Full Text] [Related]

  • 14. Alendronate disturbs vesicular trafficking in osteoclasts.
    Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K.
    Calcif Tissue Int; 2002 Jan 01; 70(1):40-7. PubMed ID: 11907706
    [Abstract] [Full Text] [Related]

  • 15. Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats.
    Astrand J, Aspenberg P.
    Acta Orthop Scand; 2002 Jan 01; 73(1):24-30. PubMed ID: 11928907
    [Abstract] [Full Text] [Related]

  • 16. [Effects of L-threonate on bone resorption by osteoclasts in vitro].
    He JH, Tong NW, Li HQ, Wu J.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar 01; 36(2):225-8. PubMed ID: 15807273
    [Abstract] [Full Text] [Related]

  • 17. A rat model for testing pharmacologic treatments of pressure-related bone loss.
    Astrand J, Skripitz R, Skoglund B, Aspenberg P.
    Clin Orthop Relat Res; 2003 Apr 01; (409):296-305. PubMed ID: 12671515
    [Abstract] [Full Text] [Related]

  • 18. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
    van der Pluijm G, Binderup L, Bramm E, van der Wee-Pals L, De Groot H, Binderup E, Löwik C, Papapoulos S.
    J Bone Miner Res; 1992 Aug 01; 7(8):981-6. PubMed ID: 1442212
    [Abstract] [Full Text] [Related]

  • 19. A useful method to evaluate bone resorption inhibitors, using osteoclast-like multinucleated cells.
    Sugawara K, Hamada M, Hosoi S, Tamaoki T.
    Anal Biochem; 1998 Jan 15; 255(2):204-10. PubMed ID: 9451505
    [Abstract] [Full Text] [Related]

  • 20. Retinoid-induced bone thinning is caused by subperiosteal osteoclast activity in adult rodents.
    Kneissel M, Studer A, Cortesi R, Susa M.
    Bone; 2005 Feb 15; 36(2):202-14. PubMed ID: 15780946
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.